DAGOBERTO CALLEGARO

(Fonte: Lattes)
Índice h a partir de 2011
20
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/62 - Laboratório de Fisiopatologia Cirúrgica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Colaboração internacional: Inglaterra × search.filters.applied.f.dateIssued: 2020 × Revista / Livro: Multiple Sclerosis and Related Disorders × Tipo de acesso: restrictedAccess ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 103 Citação(ões) na Scopus
    Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
    (2020) WHITTAM, Daniel H.; COBO-CALVO, Alvaro; LOPEZ-CHIRIBOGA, A. Sebastian; PARDO, Santiago; GORNALL, Matthew; CICCONI, Silvia; BRANDT, Alexander; BEREK, Klaus; BERGER, Thomas; JELCIC, Ilijas; GOMBOLAY, Grace; OLIVEIRA, Luana Micheli; CALLEGARO, Dagoberto; KANEKO, Kimihiko; MISU, Tatsuro; CAPOBIANCO, Marco; GIBBONS, Emily; KARTHIKEAYAN, Venkatraman; BROCHET, Bruno; AUDOIN, Bertrand; MATHEY, Guillaume; LAPLAUD, David; THOUVENOT, Eric; COHEN, Mikael; TOURBAH, Ayman; MAILLART, Elisabeth; CIRON, Jonathan; DESCHAMPS, Romain; BIOTTI, Damien; ROSTASY, Kevin; NEUTEBOOM, Rinze; HEMINGWAY, Cheryl; FORSYTH, Rob; MATIELLO, Marcelo; WEBB, Stewart; HUNT, David; MURRAY, Katy; HACOHEN, Yael; LIM, Ming; LEITE, M. Isabel; PALACE, Jacqueline; SOLOMON, Tom; LUTTEROTTI, Andreas; FUJIHARA, Kazuo; NAKASHIMA, Ichiro; BENNETT, Jeffrey L.; PANDIT, Lekha; CHITNIS, Tanuja; WEINSHENKER, Brian G.; WILDEMANN, Brigitte; SATO, Douglas Kazutoshi; KIM, Su-Hyun; HUDA, Saif; KIM, Ho Jin; REINDL, Markus; LEVY, Michael; JARIUS, Sven; TENEMBAUM, Silvia; PAUL, Friedemann; PITTOCK, Sean; MARIGNIER, Romain; JACOB, Anu
    Objective: To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). Methods: Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model). Results: Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19(+)B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses. Conclusion: RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results.